Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site

British Journal of Cancer

Volumn 90, Issue 10, 2004, Pages 1898-1904

  Piga, A ^a,i   Nortilli, R ^b   Cetto, G L ^b   Cardarelli, N ^a   Fedeli, S Luzi ^c   Fiorentini, G ^d   D'Aprile, M ^e   Giorgi, F ^f   Parziale, A P ^g   Contu, A ^h   Montironi, R ^a   Gesuita, R ^a   Carle, F ^a   Cellerino, R ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SAN SALVATORE HOSPITAL   (Italy)

^d Ravenna Hospital   (Italy)

^e Department of Medical Oncology   (Italy)

^f Department of Medical Oncology   (Italy)

^g Fatebenefratelli Hospital of Naples   (Italy)

^h City Hospital of Sassari   (Italy)

ⁱ UNIVERSITY OF UDINE   (Italy)

Author keywords

Carcinoma of unknown primary site; Chemotherapy; Phase II study

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; PLATINUM DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE; BONE CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; EVALUATION; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER; LIVER CARCINOMA; LUNG; LUNG CARCINOMA; LYMPH NODE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; TUMOR; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; TREATMENT OUTCOME;

EID: 2942629597     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601785     Document Type: Article

References (45)

1. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN (1995) Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13: 2094-2103
2. Alberts AS, Falkson G, Falkson HC, van der Merwe MP (1989) Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients. Med Pediatr Oncol 17: 188-192
3. Altman C, Cadman E, Lenzi R (1986) An analysis of 1539 patients with unknown primary site. Cancer 57: 120-124
4. Bar-Eli M, Abbruzzese JL, Lee-Jackson D, Frost P (1993) p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res 13: 1619-1623
5. Becouarn Y, Brunei R, Barbe-Gaston C (1989) Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary. Eur J Cancer Clin Oncol 25: 861-865
6. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidas N (2000) Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 18: 3101-3107
7. Briasoulis E, Tsavaris N, Fountzilas G, Athanasiadis A, Kosmidis P, Bafaloukos D, Skarlos D, Samantas E, Pavlidis N (1998a) Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: a Hellenic Co-Operative Oncology Group Phase II Study. Oncology 55: 426-430
8. Briasoulis E, Tsokos M, Fountzilas G, Bafaloukos D, Kosmidis P, Samantas E, Skarlos D, Nicolaides C, Pavlidis N (1998b) Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 18: 1907-1914
9. Califano J, Westra WH, Koch W, Meininger G, Reed A, Yip L, Boyle JO, Lonardo F, Sidransky D (1999) Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst 91: 599-604
10. Calvert AH, Newell DR, Gumbrell LA, O'Rellly D, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
11. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
12. Culine S, Fabbro M, Ychou M, Romleu G, Cupissol D, Pinguet F (1999) Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy. Ann Oncol 10: 569-575
13. Culine S, Fabbro M, Ychou M, Romleu G, Cupissol D, Pujol H (2002) Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 94: 840-846
14. Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR (2001) A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer 91: 592-597
15. Falkson CI, Cohen GL (1998) Mitomycin C, epirubicin and cisplatin vs mitomycin C alone as therapy for carcinoma of unknown primary origin. Oncology 55: 116-121
16. Greco FA, Burris III HA, Erfand JB, Gray JR, Kaiman LA, Schreeder MT, Hainsworth JD (2000b) Carcinoma of unknown primary site. Cancer 89: 2655-2660
17. Greco FA, Burris III HA, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network Study. J Clin Oncol 20: 1651-1656
18. Greco FA, Erland JB, Morrissey LH, Burris III FA, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD (2000a) Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11: 211-215
19. Greco FA, Gray J, Burris III HA, Erland JB, Morrissey LH, Hainsworth JD (2001a) Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 7: 203-212
20. Greco FA, Hainsworth JD (2001b) Cancer of unknown primary site. In Cancer: Principles and Practice of Oncology, DeVita JrVT, Hellman S, Rosenburg SA (eds) pp 2537-2560. Philadelphia: Lippincott
21. Guardiola E, Pivot X, Tchicknavorian X, Magne N, Otto J, Thyss A, Schneider M (2001) Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial. Am J Clin Oncol 24: 372-375
22. Hainsworth JD, Greco FA (1993) Treatment of patients with cancer of an unknown primary site. N Engl J Med 329: 257-263
23. Hainsworth JD, Lennington WJ, Greco FA (2000) Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18: 632-635
24. Kelsen D, Martin DS, Colofiore J, Sawyer R, Coit D (1992) A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. Cancer 70: 1988-1992
25. Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, Vaalburg W, Vermey A (1998) Detection of unknown occult primary tumors using positron emission tomography. Cancer 82: 1160-1166
26. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordonez NG, Abbruzzese JL (1997) Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 15: 2056-2066
27. Lenzi R, Kim EE, Raber MN, Abbruzzese JL (1998) Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111 In-pentetreotide scan. Ann Oncol 9: 213-216
28. Lofts FJ, Gogas H, Mansi JL (1999) Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam). Ann Oncol 10: 1389-1392
29. Macdonald AG, Nicolson MC, Samuel LM, Hutcheon AW, Ahmed FY (2002) A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. Br J Cancer 86: 1238-1242
30. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
31. Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RS (1995) Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 13: 274-282
32. Nole F, Colleoni M, Buzzoni R, Bajetta E (1993) Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. Tumori 79: 116-118
33. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM (1977) Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4: 53-58
34. Parnis FX, Olver IN, Kotasek D, Norman J, Taylor A, Russell J, Patterson K, Keefe D, Marafioti T (2000) Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Ann Oncol 11: 883-884
35. Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N (1995) Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 15: 2563-2567
36. Pavlidis N, Kosmidis P, Skarlos D, Briassoulis E, Beer M, Theoharis D, Bafaloukos D, Maraveyas A, Fountzilas G (1992) Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study. Ann Oncol 3: 631-634
37. Rigg A, Cunningham D, Gore M, Hill M, O'Brien M, Nicolson M, Chang J, Watson M, Norman A, Hill A, Gates J, Moore H, Ross P (1997) A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Br J Cancer 75: 101-105
38. Saghatchian M, Fizazi K, Borel C, Ducreux M, Ruffie P, Le Chevalier T, Theodore C (2001) Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation - results of a prospective study. Ann Oncol 12: 535-540
39. Schapira DV, Jarrett AR (1995) The need to consider survival, outcome, and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 155: 2050-2054
40. Schorn C, Fischer U, Luftner-Nagel S, Westerhof JP, Grabbe E (1999) MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 9: 470-473
41. Stevens KJ, Smith SL, Denley H, Finder SE, Evans AJ, Chan SY (1999) Is mammography of value in women with disseminated cancer of unknown origin? Clin Oncol (R Coll Radiol) 11: 90-92
42. Tilanus-Linthorst MM, Obdeijn AL, Bontenbal M, Oudkerk M (1997) MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat 44: 179-182
43. van der Gaast A, Verweij J, Henzen-Logmans SC, Rodenburg CJ, Stoter G (1990) Carcinoma of unknown primary, identification of a treatable subset? Ann Oncol 1: 119-122
44. Voog E, Merrouche Y, Trillet-Lenoir V, Lasset C, Peaud PY, Rebattu P, Negrler S (2000) Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 23: 614-616
45. Warner E, Goel R, Chang J, Chow W, Verma S, Dancey J, Franssen E, Dulude H, Girouard M, Correia J, Gallant G (1998) A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS). Br J Cancer 77: 2376-2380